P. Sripongpun (Beau)

524 posts

P. Sripongpun (Beau)

P. Sripongpun (Beau)

@BeauPimMD

Small 👩🏻‍⚕️ in the big 🌏 | Up and running in Hepatology & Gastroenterology

Katılım Temmuz 2020
75 Takip Edilen126 Takipçiler
P. Sripongpun (Beau)
P. Sripongpun (Beau)@BeauPimMD·
Thanks @my_ueg for the opportunity to present #GIPSU work at #UEGweek here in Berlin. Our study (Poster MP054) found that Dallas Steatosis Index (DSI) works pretty well in detecting #SLD in Thai individuals with cardiometabolic risk as well. #livertwitter
P. Sripongpun (Beau) tweet mediaP. Sripongpun (Beau) tweet mediaP. Sripongpun (Beau) tweet mediaP. Sripongpun (Beau) tweet media
English
0
1
7
845
P. Sripongpun (Beau) retweetledi
Ramon Bataller
Ramon Bataller@rabataller·
📊 How to interpret PEth blood levels for recent alcohol intake? Here’s a concise & practical table to guide you.
Ramon Bataller tweet media
English
2
52
109
14.9K
P. Sripongpun (Beau) retweetledi
Ramon Bataller
Ramon Bataller@rabataller·
🚨 Big milestone in MASLD/MASH! We now have two FDA-approved drugs: 🔸 Resmetirom (oral, THR-β agonist) 🔹 Semaglutide (weekly SC, GLP-1 RA) I made this simple side-by-side comparison 👇
Ramon Bataller tweet media
English
10
172
464
45.1K
P. Sripongpun (Beau) retweetledi
NEJM
NEJM@NEJM·
Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL #ASCO25 | @ASCO
NEJM tweet media
English
2
76
229
31.4K
P. Sripongpun (Beau) retweetledi
Dina Tiniakos
Dina Tiniakos@DinaTiniakos·
After 🔟 years, the new @EASLnews CPG on AutoImmune Hepatitis are here! 👉bit.ly/3F372Sf Liver biopsy 🔬 remains a pillar for diagnosis🎯! Congratulations to the author team 🇬🇷 🇳🇱🇬🇧 🇩🇰 🇩🇪🇪🇸🇮🇹🇭🇺 &EASL @ESP_Pathology @my_ueg @eemh_hasl @UKLiverPath @LiverPath_HPHS
Dina Tiniakos tweet media
Journal of Hepatology@JHepatology

🆕CPG in press❕ EASL Clinical Practice Guidelines on the management of autoimmune hepatitis Find it here👉bit.ly/3F372Sf @EASLnews @EASLedu

English
0
18
58
4.6K
P. Sripongpun (Beau) retweetledi
NEJM
NEJM@NEJM·
Original Article: Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY trial) nej.md/4kru98f @EASLnews | #EASLCongress
NEJM tweet media
English
0
25
73
17K
P. Sripongpun (Beau) retweetledi
Elliot Tapper
Elliot Tapper@ebtapper·
Important study in @NEJM ❤️ seeing @NoureddinMD front page! 😁for treatments to reverse #cirrhosis ⚠️careful not to over interpret negative phase 2b with *signals* 🧐everyone should learn about FGF21, a fascinating hormone at the intersection of liver metabolism and fibrogenesis
Elliot Tapper tweet media
English
5
43
145
9.9K
P. Sripongpun (Beau) retweetledi
NEJM
NEJM@NEJM·
In patients with compensated cirrhosis from metabolic dysfunction–associated steatohepatitis, efruxifermin did not significantly reduce fibrosis at 36 weeks. Full SYMMETRY trial results: nej.md/4kru98f @EASLnews | #EASLCongress
NEJM tweet media
English
0
11
36
15.1K
P. Sripongpun (Beau)
P. Sripongpun (Beau)@BeauPimMD·
Screening for SLD in general practice, DSI using routinely available parameters provides an impressive diagnostic accuracy. We’re more than welcome #EASLCongress attendees to visit our poster at FRI-009 Public Health zone. 😊 #GIPSU #livertwitter #EASL2025
P. Sripongpun (Beau) tweet media
English
1
1
16
870